Anxiety and depressive symptoms among COVID-19 patients admitted to three isolation facilities in Bangladesh

Md Hafizur Rahman1, Goutom Banik1, Anisuddin Ahmed1, Shams El Arifeen1, Aniqa Tasnim Hossain1, Md Aminul Hasan2 and Ahmed Ehsanur Rahman1

Abstract
The COVID-19 pandemic can impose a profound impact on the mental health of hospitalised patients infected with SARS-CoV-2. However, there have been no studies that explored the psychological distress of the COVID-19 inpatients in Bangladesh. Therefore, this study aimed to assess the prevalence of anxiety and depressive symptoms and explore the associated factors among inpatients with COVID-19. A cross-sectional study was conducted among 138 COVID-19 patients admitted to three isolation facilities in Dhaka, Bangladesh, from September to October 2020. Participants' sociodemographic and clinical data were obtained. Mental health symptoms were evaluated with the Hospital Anxiety and Depression Scale (HADS). Descriptive statistics, bivariate and multivariate logistic regression models were performed to analyse the data. The prevalence of anxiety and depressive symptoms were 57.2% (95% CI: 48.2–65.2) and 52.2% (95% CI: 43.8–62.7), respectively. Presence of comorbidity (aOR: 5.64, 95% CI: 2.21–14.35) and having ≥3 COVID-19 physical symptoms (aOR: 6.90, 95% CI: 2.71–17.56) were associated with anxiety symptoms. Besides, presence of comorbidity (aOR: 2.73, 95% CI: 1.07–6.99), having ≥3 COVID-19 physical symptoms (aOR: 4.46, 95% CI: 1.78–11.20) and patient with ≤93% oxygen saturation (aOR: 2.33, 95% CI: 1.01–5.36) were associated with depressive symptoms. Considerable numbers of COVID-19 patients in Bangladesh experienced psychological distress during hospitalisation, requiring more attention and timely mental health interventions.

Keywords
Depression, anxiety, inpatient, COVID-19, HADS, Bangladesh

Introduction
Since the dawn of 2020, the world has been experiencing a significant challenge of a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the highly contagious coronavirus disease-2019 (COVID-19). Since its discovery, nearly 124 million confirmed cases of COVID-19 have been identified worldwide, including an estimated 2.7 million deaths in about 217 countries (World Health Organization (WHO), 2020c). Bangladesh has been suffering from this highly transmissible zoonotic disease since March 2020. As of 25 March 2021, 584,395 confirmed COVID-19 cases in Bangladesh, of which 8797 died (Director General of Health Services (DGHS), 2020).

Corresponding author:
Md Hafizur Rahman, Senior Research Assistant, Maternal and Child Health Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh

Senior author:
Ahmed Ehsanur Rahman, Maternal and Child Health Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b).
Viral respiratory infections are linked to chronic and acute psychological effects among the survivors (Bohmwald et al., 2018). According to earlier studies, a large number of severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)-infected patients experienced several psychological symptoms, including posttraumatic stress, insomnia, depression, anxiety and even suicidality (Kim et al., 2018; Li and Zhang, 2003; Sheng et al., 2005). After discharge, many of these patients’ mental disturbances persisted and continued for a long time (Lam et al., 2009).

However, the psychiatric effect of previous coronavirus outbreaks can be outweighed by the COVID-19 pandemic due to the widespread circulation of falsification on social media (Zarocostas, 2020), and scarcity of medical facilities (Sommer and Bakker, 2020). COVID-19-infected patients are isolated due to their high level of transmissibility and are mainly treated in hospital facilities. While being treated in isolation, lack of interaction with friends, family, or loved ones may produce mental instability among people with COVID-19 (Li et al., 2020). Besides, recent findings have demonstrated prevailing acute psychiatric symptoms among patients admitted to intensive care units (ICUs) and required mechanical ventilation (Jackson and Khan, 2015; Hatch et al., 2018). Because of the high rate of admission (Abate et al., 2020) and prolonged length of stay in the ICU of a patient infected with SARS-CoV-2 (Rees et al., 2020), COVID-19 patients requiring ICU admission may eventually become susceptible to develop psychological distress (Sommer and Bakker, 2020). A recent systematic review reported that the pooled prevalence of depression and anxiety among COVID-19 patients was 45% and 47%, respectively (Deng et al., 2020). High levels of posttraumatic symptoms have also been identified in medically stabilised people released from the hospital following the COVID-19 recovery (Bo et al., 2020).

In Bangladesh, COVID-19 also imposed psychological consequences (Mamun et al., 2021). Suicidal deaths of a suspected COVID-19 patient at a Bangladeshi hospital were reported due to treatment-related negligence (Mamun et al., 2020), indicating the presence of serious psychological distress among COVID-19 patients in Bangladesh. As a result, this long-term psychological distress could pose a significant socioeconomic threat such as loss of productivity, human capital cost and slow economic growth of the post-pandemic world (Trautmann et al., 2016), primarily in developing countries like Bangladesh. Furthermore, depression may make the prognosis of COVID-19 worse as mental depression and distress negatively affect the patients’ immunity (Leonard, 2001). Despite its increasing significance, present estimates on the prevalence of psychological distress, such as anxiety and depressive symptoms, among COVID-19 patients are uncertain (Deng et al., 2020; Rogers et al., 2020).

To date, no studies have been conducted regarding the prevalence and associated factors of anxiety and depressive symptoms among inpatients with COVID-19 in Bangladesh. However, we hypothesised that COVID-19 inpatients would demonstrate a high rate of psychological distress, including depression and anxiety, considering the scant reported findings on COVID-19 and evidence of SARS and MERS outbreaks. Therefore, this study aimed to assess the prevalence of anxiety and depressive symptoms and explore the factors associated with anxiety and depressive symptoms among inpatients with COVID-19.

Methods

Study design, setting and participants

This cross-sectional study was conducted among 138 inpatients with COVID-19 in three COVID-19 isolation facilities, including Mugda Medical College Hospital (MMCH), Kurmitola General Hospital (KGH) and Kuwait Bangladesh Friendship Government Hospital (KBFGH). MMCH and KGH are tertiary level facilities, and KBFGH is a secondary level hospital, and all these facilities are located in Dhaka, Bangladesh. A total of 989 COVID-19-infected patients were admitted to these facilities during the data collection period (Director General of Health Services (DGHS), 2020). The non-random sampling technique was followed with a 7.7% margin of error. All of the enrolled participants were definitive COVID-19 patients diagnosed by an RT-PCR laboratory test. The present study did not include patients with the following conditions: critical symptoms, impaired awareness, mechanical ventilation, oxygen therapy, severe psychological distress and dementia (Figure 1).

Data collection

International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) in collaboration with the Director General of Health Services (DGHS), Bangladesh has been implementing a psychological support project entitled “Psychological Support to Healthcare Providers and COVID-19 Infected Patients” in Bangladesh to maintain the psychological health of the healthcare providers and patients with COVID-19. As part of the project, a survey was carried out in MMCH, KGH and KBFGH between 14 September 2020 and 19 October 2020 by seven well-trained psychiatric social workers who had been volunteering to provide psychological support to COVID-19 inpatients at those COVID-19 isolation facilities upon permission from Director of Hospital and Clinical Services, Bangladesh. Data collectors received 2 days of online training by expert trainers on the data collection tools and methods. A trained research assistant was recruited to ensure data quality, and the accuracy, consistency and completeness of the obtained data were checked. Verbal
informed consent was taken from all the participants before commencing the interview. Participants were allowed to withdraw themselves from the survey at any time, and all the identifiable information of the participants were kept confidential. The study was conducted as per the guidelines of the Helsinki Declaration, 1975.

**Measures**

**Sociodemographic and clinical information:** Sociodemographic variables included gender, age, profession, level of education, marital status and residential status. Clinical variables included the World Health Organization (WHO)–reported physical symptoms of COVID-19 (World Health Organization (WHO), 2020b) and comorbidities discussed in previous literature (Guan et al., 2020). Other clinical variables consisted of inpatient days, home member diagnosed with COVID-19 positive, oxygen saturation at rest, symptoms change after hospitalisation, history of smoking and alcohol drinking and body mass index (BMI). BMI was calculated using the formula (weight (kg)/squared of height (m2)). According to the WHO’s definition (World Health Organization (WHO), 2020a), BMI ≤18.5 kg m-2, 18.6–24.9 kg m-2, 25–29.9 kg m-2 and ≥30 kg m-2 were classified as underweight, normal weight, overweight and obese, respectively.

**Hospital Anxiety and Depression Scale (HADS):** A Bengali version of the HADS scale, a self-reported screening tool, was used to identify anxiety and depressive symptoms among the COVID-19 inpatients (Snaith, 2003). The tool consists of 14 items across two subscales: HADS-A for anxiety and HADS-D for depression. It uses a 4-point Likert scale in each subscale with a cumulative score of 0–21. This screening tool has been validated and has good reliability (mean Cronbach’s alpha=0.83 for HADS-A and mean Cronbach’s alpha=0.82 for HADS-D) in different medical settings (Bjelland et al., 2002; Al Aseri et al.,...
Prevalence of anxiety and depressive symptoms. The average score of HADS-D and HADS-A was 9.11 (SD=3.76) and 9.01 (SD=4.27), respectively. Overall, anxiety symptoms (HADS-A ≥8) was present in 57.2% (95% CI: 48.2–65.2) of the participants and depressive symptoms (HADS-D ≥8) was present in 52.2% (95% confidence interval (CI): 43.8–62.7) of the participants. Besides, 43.5% (95% CI: 34.1–53.3) of the participants had anxiety and depressive symptoms. Among the participants who were diagnosed with anxiety and depressive symptoms, the majority had a moderate level of anxiety (32.6%) and depressive (29%) symptoms (Figure 2).

Factors associated with anxiety and depressive symptoms. Multivariate logistic regression analysis showed that presence of comorbidity (adjusted odds ratio (aOR): 5.64, 95% CI: 2.21–14.35, p<0.001) and having ≥3 COVID-19 physical symptoms (aOR: 6.90, 95% CI: 2.71–17.56, p<0.001) were associated with anxiety symptoms. Besides, presence of comorbidity (aOR: 2.73, 95% CI: 1.07–6.99, p<0.05), having ≥3 COVID-19 physical symptoms (aOR: 4.46, 95% CI: 1.78–11.20, p<0.01) and patient with ≤93% oxygen saturation (aOR: 2.33, 95% CI: 1.01–5.36, p<0.05) were associated with depressive symptoms (Table 3).

Discussion
To our knowledge, this is the first survey to explore the immediate psychiatric status among COVID-19 inpatients and its associated factors in Bangladesh. The present study found that over half of the participants had anxiety (57.2%) and depressive (52.2%) symptoms, with a substantial number showing mild to severe symptoms of anxiety and depression. This rate was higher than that reported in a recent meta-analysis of 31 studies, which showed that the prevalence of anxiety and depressive symptoms among patients with COVID-19 were 47% and 45%, respectively (Deng et al., 2020). Compared to the previous studies in developing countries among COVID-19 patients in isolation, the prevalence of anxiety symptoms in the present study was higher than study conducted in Iran; 29.27% (Zarghami et al., 2020) and Wuhan, China; 18.6% (Dai et al., 2020), lower than study conducted in Iran; 100% (Zandifar et al., 2020), and coherent with a study conducted in Ecuador; 58.1% (Paz et al., 2020). Besides, the prevalence of depressive symptoms in the present study was higher than studies conducted in Jordan; 44% (Samrah et al., 2020), Wuhan, China; 13.4% (Dai et al., 2020) and Hubei, China; 43.1% (Ma et al., 2020), lower than study conducted in Iran; 97.2% (Zandifar et al., 2020), and coherent with a study conducted in Ecuador; 52.6% (Paz et al., 2020). However, these studies consisted of different sociodemographic compositions and used different study designs and
measuring instruments. Therefore, the result may vary due to different sociodemographic samples, study design and measuring instruments. Compared to the earlier study among the general citizens during the pandemic of COVID-19 in Bangladesh, both the prevalence of anxiety (57.2% vs 46.0%) and depressive (52.2% vs 47.2%) symptoms in the present study was high (Zubayer et al., 2020). Zubayer et al. also reported that the anxiety and stress were more among the population aged >30 years. This result suggests that the COVID-19 inpatients with anxiety and depressive symptoms may already have this psychological distress before they were so ill to be hospitalised.

This high prevalence of anxiety and depressive symptoms among Bangladeshi COVID-19 inpatients could be because of the incompetent healthcare system; shortage of beds, ICU, and ventilator (Sayeed Al-Zaman, 2020); treatment-related negligence in the healthcare facilities (Mamun et al., 2020); less social interaction (Li et al., 2020) and rampant circulation of misinformation on social and conventional media (Zarocostas, 2020). Moreover, symptoms of depression and anxiety among COVID-19 inpatients could increase due to uncertainty about the prognosis of the disease and the experiencing the adverse outcomes. Furthermore, side effects of COVID-19 medication and physical discomfort may also promote psychiatric problems among COVID-19 inpatients.

Our analysis revealed that having COVID-19-related physical symptoms were associated with anxiety and depressive symptoms among inpatients in COVID-19 isolation facilities (Table 3). This finding was supported by a similar study conducted in Wuhan, China, which reported that inpatients with physical symptoms of COVID-19 were more susceptible to psychological distress (Dai et al., 2020). This could be explained because COVID-19

| Table 1: Sociodemographic characteristics of the inpatients infected with COVID-19 |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|----------------|----------------|
| Variables                      | Total sample n (%)              | Yes n (%) | No n (%) | p-value | Yes n (%) | No n (%) | p-value |
| Gender                         |                                 |           |         |         |           |         |         |
| Male                           | 71 (51.4)                       | 39 (54.9) | 32 (45.1) | 0.505  | 38 (53.5) | 33 (46.5) | 0.363  |
| Female                         | 67 (48.6)                       | 33 (49.3) | 34 (50.7) |         | 41 (61.2) | 26 (38.8) |         |
| Age                            |                                 |           |         |         |           |         |         |
| 20–29 years                    | 15 (10.9)                       | 6 (40.0)  | 9 (60.0)  | **0.025** | 6 (40.0)  | 9 (60.0)  | **0.243** |
| 30–39 years                    | 27 (19.6)                       | 8 (29.6)  | 19 (70.4) |         | 12 (44.4) | 15 (55.6) |         |
| 40–49 years                    | 25 (18.1)                       | 12 (48.0) | 13 (52.0) |         | 15 (60.0) | 10 (40.0) |         |
| 50–59 years                    | 36 (26.1)                       | 23 (63.9) | 13 (36.1) |         | 24 (66.7) | 12 (33.3) |         |
| >=60 years                     | 35 (25.4)                       | 23 (65.7) | 12 (34.3) |         | 22 (62.9) | 13 (37.1) |         |
| Profession                     |                                 |           |         |         |           |         |         |
| Healthcare provider            | 9 (6.5)                         | 4 (44.4)  | 5 (55.6)  | **0.591** | 5 (55.6)  | 4 (44.4)  | **0.016** |
| Private job                    | 32 (23.2)                       | 14 (43.8) | 18 (56.3) |         | 18 (56.3) | 14 (43.8) |         |
| Student                        | 3 (2.2)                         | 1 (33.3)  | 2 (66.7)  |         | 1 (33.3)  | 2 (66.7)  |         |
| Business                       | 18 (13.0)                       | 10 (55.6) | 8 (44.4)  |         | 7 (38.9)  | 11 (61.1) |         |
| Government job                 | 13 (9.4)                        | 6 (46.2)  | 7 (53.8)  |         | 5 (38.5)  | 8 (61.5)  |         |
| Homemaker                      | 12 (8.7)                        | 5 (41.7)  | 7 (58.3)  |         | 4 (33.3)  | 8 (66.7)  |         |
| Unemployed                     | 51 (37.0)                       | 32 (62.7) | 19 (37.3) |         | 39 (76.5) | 12 (23.5) |         |
| Marital status                 |                                 |           |         |         |           |         |         |
| Single                         | 10 (7.2)                        | 3 (30.0)  | 7 (70.0)  | **0.303** | 4 (40.0)  | 6 (60.0)  | **0.484** |
| Married                        | 124 (89.9)                      | 67 (54.0) | 57 (46.0) |         | 73 (58.9) | 51 (41.1) |         |
| Divorced or widowed            | 3 (2.2)                         | 2 (66.7)  | 1 (33.3)  |         | 2 (66.7)  | 1 (33.3)  |         |
| Level of education             |                                 |           |         |         |           |         |         |
| Graduation or above            | 70 (50.7)                       | 29 (41.4) | 41 (58.6) | **0.067** | 35 (50.0) | 35 (50.0) | **0.175** |
| Higher secondary               | 44 (31.9)                       | 28 (63.6) | 16 (36.4) |         | 27 (61.4) | 17 (38.6) |         |
| Primary                        | 11 (8.0)                        | 7 (63.6)  | 4 (36.4)  |         | 9 (81.8)  | 2 (18.2)  |         |
| No schooling                   | 12 (8.7)                        | 8 (66.7)  | 4 (33.3)  |         | 8 (66.7)  | 4 (33.3)  |         |
| Residential status             |                                 |           |         |         |           |         |         |
| With family                    | 131 (94.9)                      | 69 (52.7) | 62 (47.3) | **0.709** | 76 (58.0) | 55 (42.0) | **0.461** |
| Single person and live with multiple peers | 7 (5.1) | 3 (42.9) | 4 (57.1) | 0.351 | 3 (42.9) | 4 (57.1) | 0.351 |

n=Frequencies.
*aChi-square test.
*bFisher’s exact test.
Symptoms like fever, shortness of breath, and headache can produce mental effects among patients (Fitzgerald, 2020). Symptoms of psychological distress like anxiety and depression were also more prevalent among patients with more clinical symptoms and severity of disease (Da Silva et al., 2011; Piontek et al., 2019). Thus, patients with more symptoms could be more worried about the prognosis of the disease.

Besides, the present study also found a higher rate of depressive symptoms among COVID-19 inpatients with ≤93% of oxygen saturation at rest (Table 2 and Table 3), which is consistent with a similar study conducted in China among COVID-19 patients (Kong et al., 2020). Patients with depressive symptoms have been reported to have periventricular white matter lesions (Campbell and Coffey, 2001), caused by low arterial oxygen saturation (Van Dijk et al., 2004). Oxygen saturation is considered one of the key indicators to define the clinical severity of the COVID-19 case (World Health Organization (WHO), 2020b). Low oxygen saturation might worsen the clinical condition of the patients and thus could exacerbate adverse psychological outcomes among these COVID-19 patients. More psychological and health care is needed to provide these critically ill patients with low oxygen saturation.

The present study also found that COVID-19 inpatients with comorbidity were more likely to have anxiety and depressive symptoms than those who did not have a comorbidity (Table 3). The same result was also found in a study among people living in Bangladesh during the COVID-19 pandemic (Mamun et al., 2021). Since comorbidities are expected to exacerbate because of the effects of SARS-CoV-2 infection (Chen et al., 2020), it is conceivable that patients

| Table 2. Clinical information of inpatients infected with COVID-19. |
|-----------------------------|-----------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Variables                   | Total sample n (%) | Depressive symptoms | Anxiety symptoms |
|                            | Yes n (%) | No n (%) | p-value | Yes n (%) | No n (%) | p-value |
| BMI (kg/m²)                 | Total sample n (%) | Yes n (%) | No n (%) | p-value | Yes n (%) | No n (%) | p-value |
| Underweight (<18.5)        | 1 (0.7) | 1 (100) | 0 (0) | 0.351b | 1 (100) | 0 (0) | 0.120b |
| Normal weight (18.5–24.9)  | 44 (31.9) | 27 (61.4) | 17 (38.6) | 0.341b | 34 (77.3) | 10 (22.7) | |
| Overweight (25–29.9)       | 40 (29.0) | 18 (45.0) | 22 (55.0) | 0.223b | 22 (55.0) | 18 (45.0) | |
| Obese (≥30)                | 31 (22.5) | 18 (58.1) | 13 (41.9) | 0.151b | 18 (58.1) | 13 (41.9) | |
| Inpatient days             | Total sample n (%) | Yes n (%) | No n (%) | p-value | Yes n (%) | No n (%) | p-value |
| ≤7 days                    | 72 (52.2) | 37 (51.4) | 35 (48.6) | 0.476* | 43 (60.7) | 41 (39.3) | 0.664* |
| 8–14 days                  | 44 (31.9) | 21 (47.7) | 23 (52.3) | 0.352b | 22 (50.0) | 22 (50.0) | |
| ≥15 days                   | 22 (15.9) | 14 (63.6) | 8 (36.4) | 0.664* | 14 (63.6) | 8 (36.4) | |
| Home member diagnosed with COVID-19 positive | Total sample n (%) | Yes n (%) | No n (%) | p-value | Yes n (%) | No n (%) | p-value |
| Yes                        | 38 (27.9) | 19 (50.0) | 19 (50.0) | 0.831* | 17 (44.7) | 21 (55.3) | 0.082* |
| No                         | 98 (72.1) | 51 (52.0) | 47 (48.0) | 0.600b | 60 (61.2) | 38 (38.8) | |
| Oxygen saturation at rest   | Total sample n (%) | Yes n (%) | No n (%) | p-value | Yes n (%) | No n (%) | p-value |
| ≥94%                       | 75 (54.3) | 31 (41.3) | 44 (58.7) | 0.003* | 34 (45.3) | 41 (54.7) | 0.004* |
| ≤93%                       | 60 (43.5) | 40 (66.7) | 20 (33.3) | 0.004* | 42 (70.0) | 18 (30.0) | |
| Presence of at least a comorbidity | Total sample n (%) | Yes n (%) | No n (%) | p-value | Yes n (%) | No n (%) | p-value |
| Yes                        | 85 (61.6) | 55 (64.7) | 30 (35.3) | <0.001* | 63 (74.1) | 22 (25.9) | <0.001* |
| No                         | 53 (38.4) | 17 (32.1) | 36 (67.9) | 0.375b | 16 (30.2) | 37 (69.8) | |
| Number of current physical COVID-19 symptoms | Total sample n (%) | Yes n (%) | No n (%) | p-value | Yes n (%) | No n (%) | p-value |
| ≤2                         | 52 (37.7) | 13 (25.0) | 39 (75.0) | <0.001* | 13 (25.0) | 39 (75.0) | <0.001* |
| ≥3                         | 86 (62.3) | 59 (68.6) | 27 (31.4) | 0.006* | 66 (76.7) | 20 (23.3) | |
| Symptoms change after hospitalisation | Total sample n (%) | Yes n (%) | No n (%) | p-value | Yes n (%) | No n (%) | p-value |
| Better                     | 135 (97.8) | 70 (51.9) | 65 (48.1) | 0.990b | 77 (57.0) | 58 (43.0) | 0.990b |
| Worse                      | 3 (2.2) | 2 (66.7) | 1 (33.3) | 0.004b | 2 (66.7) | 1 (33.3) | |
| Smoking history            | Total sample n (%) | Yes n (%) | No n (%) | p-value | Yes n (%) | No n (%) | p-value |
| Yes                        | 32 (23.2) | 19 (59.4) | 13 (40.6) | 0.352* | 17 (53.1) | 15 (46.9) | 0.591* |
| No                         | 106 (76.8) | 53 (50.0) | 53 (50.0) | 0.352* | 62 (58.5) | 44 (41.5) | |
| Alcohol drinking history   | Total sample n (%) | Yes n (%) | No n (%) | p-value | Yes n (%) | No n (%) | p-value |
| Yes                        | 4 (2.9) | 3 (75.0) | 1 (25.0) | 0.621b | 1 (25.0) | 3 (75.0) | 0.313b |
| No                         | 134 (97.1) | 69 (51.5) | 65 (48.5) | 0.831b | 78 (58.2) | 56 (41.8) | |

BMI=Body Mass Index.

*aChi-square test.

bFisher’s exact test.
with comorbidities can experience more psychological distress than those with fewer or no comorbidities.

In this study, higher rates of depressive symptoms were found among older age. Both the anxiety and depressive symptoms were more prevalent among participants aged 50 years or above (Table 1). It was also evident that the suicidal cases among the older population spiked during the SARS epidemic in 2003 (Yip et al., 2010). However, this finding was coherent with a previous study conducted in Spain among a population aged over 60 years at the time of the

**Table 3.** Bivariate and multivariate logistic regression analysis of factors associated with anxiety and depressive symptoms among inpatients infected with COVID-19.

| Variables                           | Crude odds ratio (95% CI) | p-value | Adjusted odds ratio (95% CI) | p-value |
|-------------------------------------|---------------------------|---------|-----------------------------|---------|
| **Model for anxiety symptoms**      |                           |         |                             |         |
| Inpatient days                      |                           |         |                             |         |
| ≤7 days                             | 1                         |         | 1                           |         |
| 8-14 days                           | 0.67 (0.32-1.44)          | 0.310   | 0.49 (0.18-1.30)            | 0.152   |
| ≥15 days                            | 1.18 (0.44-3.17)          | 0.740   | 0.63 (0.17-2.34)            | 0.491   |
| Home member diagnosed with COVID-19 |                           |         |                             |         |
| No                                  | 1                         |         | 1                           |         |
| Yes                                 | 0.51 (0.24-1.09)          | 0.084   | 0.40 (0.15-1.09)            | 0.074   |
| Oxygen saturation at rest           |                           |         |                             |         |
| ≥94%                                | 1                         |         | 1                           |         |
| ≤93%                                | 2.81 (1.38-5.75)          | 0.005   | 1.99 (0.80-4.95)            | 0.137   |
| Comorbidity                         |                           |         |                             |         |
| No                                  | 1                         |         | 1                           |         |
| Yes                                 | 6.62 (3.09-14.18)         | <0.001  | 5.64 (2.21-14.35)           | <0.001  |
| Number of current physical COVID-19 |                           |         |                             |         |
| ≤2 symptoms                         | 1                         |         | 1                           |         |
| ≥3 symptoms                         | 9.90 (4.44-22.09)         | <0.001  | 6.90 (2.71-17.56)           | <0.001  |
| **Model for depressive symptoms**   |                           |         |                             |         |
| Age                                 |                           |         |                             |         |
| 20-29 years                         | 1                         |         | 1                           |         |
| 30-39 years                         | 0.63 (0.17-2.37)          | 0.496   | 0.19 (0.04-0.96)            | 0.054   |
| 40-49 years                         | 1.39 (0.38-5.07)          | 0.623   | 0.31 (0.06-1.48)            | 0.414   |
| 50-59 years                         | 2.65 (0.77-9.14)          | 0.122   | 0.70 (0.15-3.16)            | 0.641   |
| ≥60 years                           | 2.88 (0.83-10.00)         | 0.097   | 0.69 (0.14-3.40)            | 0.651   |
| Oxygen saturation at rest           |                           |         |                             |         |
| ≥94%                                | 1                         |         | 1                           |         |
| ≤93%                                | 2.84 (1.4-5.76)           | 0.004   | 2.33 (1.01-5.36)            | 0.047   |
| Comorbidity                         |                           |         |                             |         |
| No                                  | 1                         |         | 1                           |         |
| Yes                                 | 3.88 (1.87-8.04)          | <0.001  | 2.73 (1.07-6.99)            | 0.036   |
| Number of current physical COVID-19 |                           |         |                             |         |
| ≤2 symptoms                         | 1                         |         | 1                           |         |
| ≥3 symptoms                         | 6.56 (3.02-14.24)         | <0.001  | 4.46 (1.78-11.20)           | 0.001   |

Figure 2: Severity of anxiety and depressive symptoms among COVID-19 inpatients in Bangladesh.

Table 3. Bivariate and multivariate logistic regression analysis of factors associated with anxiety and depressive symptoms among inpatients infected with COVID-19.
COVID-19 outbreak (Picaza Gorrochategi et al., 2020). This could be because the older age group has a higher risk of COVID-19 infection and death (Adhikari et al., 2020). Since psychological distress has an adverse effect on the body’s immunity (Leonard, 2001), this higher prevalence of anxiety and depressive symptoms could worsen the prognosis of COVID-19 among these already vulnerable populations. Therefore, particular focus should be placed on psychiatric interventions aiming at the older age group.

Although female patients reported having more psychological distress like depression and anxiety than their male counterparts before the COVID-19 outbreak (Abate, 2013), no significant gender differences were found associated with depression and anxiety in the present study. This result is coherent with studies conducted in Iran among patients with COVID-19 (Zandifar et al., 2020; Zarghami et al., 2020). Gender variations could be neutralised in the current study because of the small sample size and circumstances of the COVID-19 pandemic.

Self-rating scales were used in this study rather than a web-based survey to explore the psychological distress comprehensively so that patients, especially the older ones who did not have access to the internet or smartphone, could participate in the study. However, there were some certain limitations to our study. Firstly, because of the restricted interaction with COVID-19 patients, only three isolation facilities were surveyed. The study used a non-random sampling technique and a small sample size that may limit the generalisation of the findings and increase the risk of selection bias. Besides, the present study lacked clinical interviews to confirm the diagnosis of anxiety and depression. Therefore, the findings could be influenced by the high infectivity nature of COVID-19 and the presence of somatic symptoms. For further verification of our findings, a multi-facility study with greater sample size is required. Secondly, since this was a cross-sectional study, dynamic observation and follow-up of the participant’s psychological outcomes were not carried out. The causal relationships between the outcome variable and associated factors could not be explored. Thirdly, only some of the factors associated with mental health were assessed in this study, and further research on other possible factors is required. Lastly, HADS present study did not have any control inpatient group to compare the prevalence and severity of anxiety and depressive symptoms.

In conclusion, the findings have shown that substantial numbers of COVID-19 patients in Bangladesh experienced psychological distress during hospitalisation. Therefore, we recommend addressing the psychological health problem among COVID-19 inpatients by giving more attention and timely psychological interventions. Early identification and appropriate treatments like psychological counselling, long-term assessment and information about where to get support are needed to be delivered in a timely fashion to COVID-19 inpatients. Behavioural change communication interventions are also required to promote healthcare-seeking behaviour for mental health.

Acknowledgement
The authors wish to thank the Director General of Health, Bangladesh (DGHS), for the permission and supports to conduct the study. The authors express their appreciation to all the patients for their participation and healthcare providers for their cooperation. We thank Dr. Dewan Md. Emdadul Hoque and Md. Azmal Hossain from UNFPA for the acquisition of the financial support for the project. We are thankful to Ema Akter from icddr,b, for her support in analysis. We are also thankful to Shima Akter, Yaqub Hasan, Rezaul Karim Badol, Rayhan Shorab Uday, Rishat Mridha, Estiak Ahmed and Arup Anindya for collecting the data.

Author contribution
Conceptualisation: MR, GB; Data curation: MR, GB and MH; Formal analysis: MR; Investigation: GB, AR, AA, SA and MH; Resources: GB and MH; Validation: GB, AH, AR and AA; Writing – original draft: MR, GB and AH; Writing – review & editing: GB, AH, AR and AA.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by United Nations Population Fund (UNFPA).

Ethical approval
Ethical aspects of this study were reviewed and approved by the Institutional Ethical Committee, Department of Environmental Sanitation, Patuakhali Science and Technology University, Bangladesh (reference no.: ENS22/11/2020:006).

ORCID iD
Md Hafizur Rahman https://orcid.org/0000-0002-2742-049X

References
Abate KH (2013) Gender disparity in prevalence of depression among patient population: a systematic review. Ethiopian Journal of Health Sciences. College of Public Health and Medical Sciences of Jimma University 23(3): 283–288.
Abate S M, Ali SA, Mantfardo B, et al. (2020) Rate of Intensive Care Unit admission and outcomes among patients with coronavirus: a systematic review and Meta-analysis Plos One. Public Library of Science, 15(7). doi: 10.1371/journal.pone.0235653. In press.

Adhikari SP, Meng S, Wu Y-J, et al. (2020) Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infectious Diseases of Poverty. BioMed Central Ltd., 9, 29. Available at: https://idpjournal.biomedcentral.com/articles/10.1186/s40249-020-0.

Annunziata MA, Muzzatti B, Bidoli E, et al. (2020) Hospital anxiety and depression scale (HADS) accuracy in cancer patients. Supportive Care in Cancer. Springer 28(8): 3921–3926.

Al Aseri ZA, Suriya MO, Hassan HA, et al. (2015) Reliability and validity of the hospital anxiety and depression scale in an emergency department in Saudi Arabia: a cross-sectional observational study. BMC Emergency Medicine. BioMed Central Ltd, 20, 9–9.

Bjelland I, Dahl AA, Haug TT, et al. (2002) The validity of the hospital anxiety and depression scale: an updated literature review. Journal of Psychosomatic Research 52(2): 69–77.

Bo HX, Li W, Yang Y, et al. (2020) Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychological Medicine. Cambridge University Press 51(6): 1052–1053.

Bohmwald K., Gálvez N. M. S., Rá Al Aseri Z, Suriya MO, Hassan HA, et al. (2015) Reliability and validity of the hospital anxiety and depression scale in an emergency department in Saudi Arabia: a cross-sectional observational study. BMC Emergency Medicine. BioMed Central Ltd, 20, 9–9.

Byelland I, Dahl AA, Haug TT, et al. (2002) The validity of the hospital anxiety and depression scale: an updated literature review. Journal of Psychosomatic Research 52(2): 69–77.

Bjelland I, Dahl AA, Haug TT, et al. (2002) The validity of the hospital anxiety and depression scale: an updated literature review. Journal of Psychosomatic Research 52(2): 69–77.

Bo HX, Li W, Yang Y, et al. (2020) Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychological Medicine. Cambridge University Press 51(6): 1052–1053.

Bohmwald K., Gálvez N. M. S., Rá Al Aseri Z, Suriya MO, Hassan HA, et al. (2015) Reliability and validity of the hospital anxiety and depression scale in an emergency department in Saudi Arabia: a cross-sectional observational study. BMC Emergency Medicine. BioMed Central Ltd, 20, 9–9.

Byelland I, Dahl AA, Haug TT, et al. (2002) The validity of the hospital anxiety and depression scale: an updated literature review. Journal of Psychosomatic Research 52(2): 69–77.

Bo HX, Li W, Yang Y, et al. (2020) Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychological Medicine. Cambridge University Press 51(6): 1052–1053.

Bjelland I, Dahl AA, Haug TT, et al. (2002) The validity of the hospital anxiety and depression scale: an updated literature review. Journal of Psychosomatic Research 52(2): 69–77.

Bo HX, Li W, Yang Y, et al. (2020) Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychological Medicine. Cambridge University Press 51(6): 1052–1053.

Bjelland I, Dahl AA, Haug TT, et al. (2002) The validity of the hospital anxiety and depression scale: an updated literature review. Journal of Psychosomatic Research 52(2): 69–77.

Bjelland I, Dahl AA, Haug TT, et al. (2002) The validity of the hospital anxiety and depression scale: an updated literature review. Journal of Psychosomatic Research 52(2): 69–77.

Bo HX, Li W, Yang Y, et al. (2020) Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychological Medicine. Cambridge University Press 51(6): 1052–1053.

Bjelland I, Dahl AA, Haug TT, et al. (2002) The validity of the hospital anxiety and depression scale: an updated literature review. Journal of Psychosomatic Research 52(2): 69–77.

Bo HX, Li W, Yang Y, et al. (2020) Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychological Medicine. Cambridge University Press 51(6): 1052–1053.

Bjelland I, Dahl AA, Haug TT, et al. (2002) The validity of the hospital anxiety and depression scale: an updated literature review. Journal of Psychosomatic Research 52(2): 69–77.

Bo HX, Li W, Yang Y, et al. (2020) Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychological Medicine. Cambridge University Press 51(6): 1052–1053.

Bjelland I, Dahl AA, Haug TT, et al. (2002) The validity of the hospital anxiety and depression scale: an updated literature review. Journal of Psychosomatic Research 52(2): 69–77.

Bo HX, Li W, Yang Y, et al. (2020) Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychological Medicine. Cambridge University Press 51(6): 1052–1053.

Bjelland I, Dahl AA, Haug TT, et al. (2002) The validity of the hospital anxiety and depression scale: an updated literature review. Journal of Psychosomatic Research 52(2): 69–77.

Bo HX, Li W, Yang Y, et al. (2020) Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychological Medicine. Cambridge University Press 51(6): 1052–1053.

Bjelland I, Dahl AA, Haug TT, et al. (2002) The validity of the hospital anxiety and depression scale: an updated literature review. Journal of Psychosomatic Research 52(2): 69–77.

Bo HX, Li W, Yang Y, et al. (2020) Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychological Medicine. Cambridge University Press 51(6): 1052–1053.

Bjelland I, Dahl AA, Haug TT, et al. (2002) The validity of the hospital anxiety and depression scale: an updated literature review. Journal of Psychosomatic Research 52(2): 69–77.

Bo HX, Li W, Yang Y, et al. (2020) Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychological Medicine. Cambridge University Press 51(6): 1052–1053.

Bo HX, Li W, Yang Y, et al. (2020) Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychological Medicine. Cambridge University Press 51(6): 1052–1053.

Bo HX, Li W, Yang Y, et al. (2020) Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychological Medicine. Cambridge University Press 51(6): 1052–1053.
patients under epidemiological surveillance for COVID-19 in Ecuador. *Plos One*. Public Library of Science, 15: e0240008.

Picaza Gorrochategi M., Munitis AE, Dosil Santamaria M, et al. (2020) Stress, anxiety, and depression in people aged over 60 in the COVID-19 outbreak in a sample collected in Northern Spain. *American Journal of Geriatric Psychiatry*. Elsevier B.V. 28(9): 993–998.

Piontek K, Ketels G, Albrecht R, et al. (2019) Somatic and psychosocial determinants of symptom severity and quality of life in male and female patients with chronic pelvic pain syndrome. *Journal of Psychosomatic Research*. Elsevier Inc. 120: 1–7.

Rees EM, Nightingale ES, Jafari Y, et al. (2020) COVID-19 length of hospital stay: a systematic review and data synthesis. *BMC Medicine*. BioMed Central Ltd: 270.

Rogers JP, Chesney E, Oliver D, et al. (2020) Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. *Lancet Psychiatry*. Elsevier Ltd 7(7): 611–627.

Samrah SM, Al-Mistarehi AH, Aleshawi AJ, et al. (2020) Depression and coping among covid-19-infected individuals after 10 days of mandatory in-hospital quarantine, Irbid, Jordan. *Psychology Research and Behavior Management*. Dove Medical Press Ltd 13: 823–830.

Sayeed Al-Zaman M (2020) Healthcare crisis in Bangladesh during the COVID-19 pandemic. *American Journal of Tropical Medicine and Hygiene*. American Society of Tropical Medicine and Hygiene 103(4): 1357–1359.

Sheng B, Cheng SK, Lau KK, et al. (2005) The effects of disease severity, use of corticosteroids and social factors on neuropsychiatric complaints in severe acute respiratory syndrome (SARS) patients at acute and convalescent phases. *European Psychiatry*. Elsevier Masson SAS 20(3): 236–242.

Da Silva AM, Vilhena E, Lopes A, et al. (2011) Depression and anxiety in a Portuguese MS population: associations with physical disability and severity of disease. *Journal of the Neurological Sciences*. J Neurol Sci 306: 66–70.

Snaith RP (2003) The hospital anxiety and depression scale. *Health and Quality of Life Outcomes* 1: 29.